Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

PureTech (PRTC) Share Price

Price 113.60p on 07-04-2026 at 18:50:08
Change 0.60p 0.53%
Buy 113.80p
Sell 113.00p
Last Trade: Unknown 37,500.00 at 113.60p
Day's Volume: 1,180,402
Last Close: 113.60p
Open: 115.00p
ISIN: GB00BY2Z0H74
Day's Range 112.40p - 115.40p
52wk Range: 100.40p - 148.00p
Market Capitalisation: £276.52m
VWAP: 113.93777p
Shares in Issue: 243.42m

PureTech (PRTC) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 37,500 113.60p OTC Trade
17:05:49 - 07-Apr-26
Buy* 8,000 113.60p Ordinary
16:36:44 - 07-Apr-26
Buy* 6,313 113.60p SI Trade
16:35:07 - 07-Apr-26
Sell* 80,936 113.60p Uncrossing Trade
16:35:07 - 07-Apr-26
Buy* 110 113.60p Automatic Execution
16:29:32 - 07-Apr-26
Buy* 229 113.60p Automatic Execution
16:29:28 - 07-Apr-26
Buy* 221 113.40p Automatic Execution
16:29:28 - 07-Apr-26
Buy* 1 113.40p Automatic Execution
16:29:09 - 07-Apr-26
Buy* 98 113.40p Automatic Execution
16:28:43 - 07-Apr-26
Buy* 100 113.40p Automatic Execution
16:28:03 - 07-Apr-26
See more PureTech trades

PureTech (PRTC) Share Price History

Time period:
to
Date Open High Low Close Volume
7th Apr 2026 (Tue) 115.00 115.40 112.40 113.60 1,180,402
6th Apr 2026 (Mon) 113.00 113.00 113.00 113.00 0
3rd Apr 2026 (Fri) 113.00 113.00 113.00 113.00 0
2nd Apr 2026 (Thu) 108.00 114.00 107.60 113.00 2,435,373
1st Apr 2026 (Wed) 113.00 113.00 109.40 110.00 1,277,081
31st Mar 2026 (Tue) 107.80 109.20 107.40 108.00 940,746
30th Mar 2026 (Mon) 116.20 116.20 108.00 108.00 799,681
27th Mar 2026 (Fri) 118.20 118.20 110.00 110.00 686,172
26th Mar 2026 (Thu) 115.00 115.60 113.40 114.60 293,260
25th Mar 2026 (Wed) 120.00 120.00 114.00 115.00 299,041
24th Mar 2026 (Tue) 114.00 115.20 112.40 114.20 235,278
23rd Mar 2026 (Mon) 116.00 117.40 110.80 114.00 440,265
20th Mar 2026 (Fri) 119.00 119.00 115.60 115.60 423,659
19th Mar 2026 (Thu) 118.00 118.40 115.00 117.20 357,049
18th Mar 2026 (Wed) 120.20 123.80 118.40 118.40 465,726
17th Mar 2026 (Tue) 120.60 121.80 119.20 120.80 454,813
16th Mar 2026 (Mon) 120.40 121.00 118.20 120.00 331,694
13th Mar 2026 (Fri) 123.00 123.40 121.00 121.20 168,339
12th Mar 2026 (Thu) 124.80 125.20 122.60 123.20 190,505
11th Mar 2026 (Wed) 125.00 125.60 123.40 125.20 258,623
10th Mar 2026 (Tue) 123.40 125.60 123.40 125.20 198,057
9th Mar 2026 (Mon) 123.20 123.20 120.60 122.20 262,638
See more PureTech price history

PureTech (PRTC) Regulatory News

Date Source Headline
1st Apr 2026 7:00 am RNS Total Voting Rights
25th Mar 2026 6:00 pm RNS-R PRTC’s Seaport: GlyphAllo Paper Published
13th Mar 2026 4:35 pm RNS PDMR Notification RSU Vesting
2nd Mar 2026 7:00 am RNS Total Voting Rights
25th Feb 2026 7:00 am RNS-R PRTC to Present at Leerink Healthcare Conference
19th Feb 2026 5:15 pm RNS-R PRTC's Deupirfenidone Granted FDA & EU ODD for IPF
6th Jan 2026 12:00 pm RNS-R PureTech to Present at the JP Morgan Conference
18th Dec 2025 7:00 am RNS PureTech Appoints Robert Lyne as CEO
10th Dec 2025 5:41 pm RNS Results of AGM on June 16, 2025 – Update Statement
10th Dec 2025 5:30 pm RNS Holding(s) in Company
See more PureTech regulatory news

PureTech (PRTC) Share News

EARNINGS AND TRADING: McBride proposes cash acquisition of Eurotab

2nd Apr 2026 17:50

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

PureTech says its pulmonary fibrosis drug granted orphan designation

20th Feb 2026 13:11

(Alliance News) - PureTech Health PLC said on Friday its drug treating idiopathic pulmonary fibrosis, deupirfenidone, has been designated as an orphan drug by both the US Food & Drug Administration and the European Commission. Read More

IN BRIEF: PureTech Health promotes interim CEO Robert Lyne to CEO

18th Dec 2025 11:11

PureTech Health PLC - Boston, Massachusetts-based biotech and pharmaceutical firm - Promotes interim Chief Executive Officer Robert Lyne to CEO on a permanent basis from Thursday. Lyne has served as interim CEO since July, having joined the company in January 2024 as chief portfolio officer. He has overseen progress across PureTech's programmes and advancing strategic and operational priorities. Lyne was previously CEO of Arix Bioscience PLC. Read More

FDA backs PureTech's phase 3 move for IPF drug deupirfenidone

8th Dec 2025 12:34

(Alliance News) - PureTech Health PLC on Monday said its idiopathic pulmonary fibrosis drug candidate deupirfenidone has cleared a key regulatory milestone, with the US Food & Drug Administration backing progression into a pivotal phase 3 trial planned for the first half of 2026. Read More

SMALL-CAP WINNERS: Mears rises as annual profit set to beat forecasts

8th Dec 2025 10:59

(Alliance News) - The following stocks are the leading risers among London Main Market small-caps on Monday. Read More

See more PureTech news
FTSE 100 Latest
Value10,348.79
Change-87.50

Login to your account

Forgot Password?

Not Registered